Skip to main content
    K

    Kairos Pharma, Ltd. (KAPA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.39
    -0.01 (-3.22%)

    Market Cap: $1.38M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Kairos Pharma, Ltd. (KAPA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Kairos Pharma (KAPA) has a market cap of $1.38M. Its share count is up 711.92% from a year earlier. It holds $3.13M more cash than debt, 226.86% of its market cap.

    Total Valuation

    Market Cap$1.38M
    Latest price (Nov 17, 2026)$0.39

    Key Dates

    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 9.41% in the quarter ended Sep 30, 2026 and grew 46.57% a year over 2 years.

    Shares Outstanding3.35M
    Shares Change (YoY)+711.92%
    Shares Change (QoQ)+9.41%
    Share Count Growth (2Y CAGR)+46.57%

    Price Statistics

    The stock is down 93.22% over 52 weeks and trades 61.76% below its 50-day average.

    Beta (1Y)1.57
    52-Week Change-93.22%
    1-Month Change-30.92%
    3-Month Change-81.83%
    6-Month Change-88.23%
    Total Return (1Y)-93.22%
    Max Drawdown (1Y)-94.20%
    Max Drawdown (3Y)-97.84%
    Sharpe Ratio (1Y)-2.85
    Correlation with SPY (1Y)0.24
    50-Day Average$1.02
    200-Day Average$2.75
    52-Week Range$0.41 to $7.28
    RSI (14 Days)24.2
    Average Volume (20 Days)68.11K

    Price chart

    Financial Position

    Current assets cover 6.77x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.77x
    Quick Ratio6.77x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -164.93% and return on assets is -146.25% over the last 12 months.

    Return on Equity (ROE)-164.93%
    Return on Assets (ROA)-146.25%

    Scores

    KAPA has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit$120.00K
    Operating Income-$6.53M
    Pretax Income-$6.39M
    Net Income-$6.39M
    EBITDA-$5.57M
    Reported EPS (TTM)-$1.28

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 88.79% of the $4.37M in total assets.

    Cash and Equivalents$3.13M
    Total Debt$0
    Net Cash$3.13M
    Net Cash Per Share$0.93
    Working Capital$2.85M
    Shareholder Equity$3.88M
    Book Value Per Share$1.16
    Total Assets$4.37M
    Total Liabilities$495.00K

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$4.11M
    FCF Per Share-$1.46
    Depreciation and Amortization$959.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    KAPA does not pay a dividend.

    Buyback Yield-141.79%
    Shareholder Yield-141.79%

    Stock Splits

    The last split was a 1-for-7 reverse split on Sep 1, 2026.

    Last Split DateSep 1, 2026
    Split TypeReverse split
    Split Ratio1:7

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About KAPA

    What is KAPA's market cap?

    Kairos Pharma has a market cap of $1.38M.

    How many shares of KAPA are outstanding?

    Kairos Pharma has 3.35M shares outstanding. The count is up 711.92% from a year earlier.

    Does KAPA pay a dividend?

    No. Kairos Pharma does not pay a dividend.

    How much debt does KAPA have?

    Kairos Pharma has $0 of total debt and $3.13M of cash and equivalents, a net cash position of $3.13M.